Biomarkers of demyelination and axonal damage are decreased after autologous hematopoietic stem cell transplantation for multiple sclerosis

被引:0
|
作者
Zjukovskaja, Christina [1 ]
Larsson, Anders [1 ]
Cherif, Honar [1 ]
Kultima, Kim [1 ]
Burman, Joachim [1 ]
机构
[1] Uppsala Univ, Dept Med Sci, SE-75185 Uppsala, Sweden
基金
瑞典研究理事会;
关键词
Multiple sclerosis; Autologous hematopoietic stem cell; transplantation; Demyelination; Neurofilament light chain; Myelin basic protein; Glial fibrillary acidic protein;
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Autologous hematopoietic stem cell transplantation (aHSCT) has seen increased use for relapsing -remitting multiple sclerosis (RRMS) in recent years. It is considered one of the most effective treatments for RRMS and has been associated with improvement in disability and prolonged remission. This suggests that the tissue-injuring disease process may have been altered by aHSCT. To assess whether this hypothesis is correct, we performed a study of three commonly used cerebrospinal fluid biomarkers of tissue damage.Methods: In this single center study, 63 patients treated with aHSCT at Uppsala University Hospital between January 1st 2012 and January 31st 2019 were screened for participation. A control group consisting of volun-teers without neurologic disease were included as a reference. Cerebrospinal fluid concentrations of neurofila-ment light (NFL), myelin basic protein (MBP) and glial acidic fibrillary protein (GFAp) were determined using ELISA and a multiplex proteomics platform from Meso Scale Discovery.Results: Forty-three patients with a mean age of 31 and a median follow-up time of 3.9 years were included. Their median baseline expanded disability status scale (EDSS) score was 3.5 and the annualized relapse rate in the year preceding aHSCT was 1.6. At baseline the proportion of patients with values above the upper limit of normal was 67% for NFL, 63% for MBP and 16% for GFAp. At 5-year follow-up, the proportion of patients with values above the upper limit of normal was 12% for NFL, 12% for MBP and 25% for GFAp. The mean concentration of NFL decreased from 920 pg/mL at baseline to 270 pg/mL at 5-year follow-up (p < 0.001); MBP decreased from 1500 to 680 pg/mL (p < 0.001); whereas the mean concentration of GFAp was unchanged.Conclusion: In a majority of patients, biomarkers of demyelination and axonal damage reached normal values within five years from treatment with aHSCT.
引用
收藏
页数:6
相关论文
共 50 条
  • [1] Biomarkers of demyelination and axonal damage are decreased after autologous hematopoietic stem cell transplantation for multiple sclerosis
    Zjukovskaja, Christina
    Larsson, Anders
    Cherif, Honar
    Kultima, Kim
    Burman, Joachim
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 68
  • [2] Dynamics of Inflammatory and Neurodegenerative Biomarkers after Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis
    Ruder, Josefine
    Dinner, Gianna
    Maceski, Aleksandra
    Berenjeno-Correa, Ernesto
    Mueller, Antonia Maria
    Jelcic, Ilijas
    Kuhle, Jens
    Martin, Roland
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (18)
  • [3] Neuroinflammation and Demyelination in Multiple Sclerosis After Allogeneic Hematopoietic Stem Cell Transplantation
    Lu, Jian-Qiang
    Joseph, Jeffrey T.
    Nash, Richard A.
    Storek, Jan
    Stevens, Anne M.
    Metz, Luanne M.
    Clark, Arthur W.
    Johnson, Edward S.
    Yong, V. Wee
    ARCHIVES OF NEUROLOGY, 2010, 67 (06) : 716 - 722
  • [4] INFLAMMATION AND DEMYELINATION IN MULTIPLE SCLEROSIS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
    Lu, Jian-Qiang
    Joseph, Jeffrey T.
    Nash, Richard A.
    Storek, Jan
    Stevens, Anne M.
    Metz, Luanne M.
    Clark, Arthur W.
    Johnson, Edward S.
    Yong, V. Wee
    BONE MARROW TRANSPLANTATION, 2010, 45 : S24 - S24
  • [5] Inflammation And Demyelination in Patients With Multiple Sclerosis After Allogeneic Hematopoietic Stem Cell Transplantation
    Lu, Jian-Qiang
    Joseph, Jeffrey
    Stevens, Anne
    Storek, Jan
    Nash, Richard
    Metz, Luanne
    Clark, Arthur
    Johnson, Edward
    Yong, V. Wee
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2009, 68 (05): : 576 - 576
  • [6] Evoked potentials after autologous hematopoietic stem cell transplantation for multiple sclerosis
    Katsarogiannis, Evangelos
    Axelson, Hans
    Berntsson, Shala
    Rothkegel, Holger
    Burman, Joachim
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 83
  • [7] Immune reconstitution after autologous hematopoietic stem cell transplantation in multiple sclerosis
    Ruder, Josefine
    Obahor, Simon
    Rex, Jordan
    Muller, Antonia
    Jelcic, Ilijas
    Martin, Roland
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2021, 51 : 120 - 120
  • [8] Autologous Hematopoietic Stem Cell Transplantation to Treat Multiple Sclerosis
    Ross, Lindsay A.
    Stropp, Lisa M.
    Cohen, Jeffrey A.
    NEUROLOGIC CLINICS, 2024, 42 (01) : 165 - 184
  • [9] Autologous hematopoietic stem cell transplantation: a cure for multiple sclerosis?
    Libbey, Jane E.
    Tsunoda, Ikuo
    Fujinami, Robert S.
    FUTURE NEUROLOGY, 2006, 1 (04) : 403 - 408
  • [10] Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Multiple Sclerosis
    Rush, Carolina A.
    Atkins, Harold L.
    Freedman, Mark S.
    COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2019, 9 (03):